We are excited to announce that the RIDDLE-M-X trial for newly diagnosed patients with Multiple Myeloma is now open for recruitment at Nepean Hospital and Alfred Hospital!

This study will utilise a risk and response adaptive approach to treat newly diagnosed multiple myeloma patients undergoing an autologous stem cell transplantation (ASCT). We plan to use a diagnosic proceture known as SKY92 MMProfiler to pre-screen participants to determine their MM genetic risk category in real time. We will also use another diagnostic technique called EuroFlow after ASCT to determine a parameter called minimal residual disease (MRD), which is based on the number of detectable myeloma cells. Selinexor will be added to standard PBS therapy in patients who either: 1) are categorised to have high-risk myeloma based on the SKY92 MMProfiler test, or 2) have a significant number of detectable myeloma cells (MRD positive) based on the EuroFlow test.

Please contact amarc@alfred.org.au for more information.